Eli Lilly Stock Slides. Zepbound and Mounjaro Sales Miss Estimates Again. - Barron's

1. LLY's GLP-1 drug sales missed Wall Street estimates, impacting stock negatively. 2. Mounjaro's Q4 sales were $3.5 billion, below the $4.4 billion estimate. 3. Zepbound's Q4 sales of $1.9 billion fell short of the $2.1 billion expectation. 4. Consecutive sales misses echo prior October 2024 disappointments, causing selloff. 5. 2025 revenue guidance slightly exceeds expectations, at $58-61 billion.